Recombinant FGF1 (rFGF1) administered by injection dose-dependently ameliorated insulin insensitivity and hyperinsulinemia, normalized glucose levels, and increased the hepatic glycogen content in genetically diabetic (ob/ob and db/db) and high-fat diet-induced obese insulin-resistant mice, with no hypoglycemia even at higher doses [69]. Here, INS is linked to Hyperinsulinemia.